Rhabdomyosarcoma - Pediatric Clinical Trial (05.10.029T)
COG ARST0331: Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide With or Without Radiation Therapy for Patients with Newly Diagnosed Low-Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma
Protocol ID
05.10.029T
Protocol Description
The standard treatment for rhabdomyosarcoma consists of chemotherapy, surgery, and or radiation therapy. This study is being done to find out the most effective treatment with the least amount of therapy that will still cure subjects with low risk rhabdomyosarcoma. We want to know this because although chemotherapy and radiation therapy can cure low-risk rhabdomyosarcoma, they can also have effects on subjects later in life (late effects). Late effects can include slowing of growth in children, inability to have children (sterility), and causing another cancer to develop.
Eligibility Criteria
Children and adolescents with rhabdomyosarcoma
Primary Investigator(s)
- Arlene Redner, MD